37m
Pharvaris N.V.: Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in CHAPTER-3, a pivotal Phase 3 ...
Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback